Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Fakih Fleshes Out Perceptions on Pembrolizumab Approval in TMB-High Solid Tumors

June 30th 2020

Marwan G. Fakih, MD, discusses the June 2020 FDA approval of pembrolizumab for use in select patients with unresectable or metastatic solid tumors that are tumor mutational burden–high provides a potentially life-saving option to those who have exhausted all other available therapies.

DESTINY-Lung01 Data Position Trastuzumab Deruxtecan as Next Oncogene-Driven Therapy in NSCLC

June 29th 2020

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.

Dr. Rana on Germline Genetic Testing in Advanced Prostate Cancer

June 23rd 2020

Huma Q. Rana, MD, MPH, discusses germline genetic testing in men with advanced prostate cancer.

Utility of Minimally Invasive Plasma-Based NGS Expands in NSCLC

June 23rd 2020

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

Survivin Isoforms Detection Predicts a Potential Role in Tumor Biology

June 22nd 2020

Three main survivin isoforms demonstrated the ability to translocate to the surface of plasma membrane in multiple cell types, suggesting a targetable role as a molecular biomarker.

Guidelines Recommend Widespread Genetic Testing for Metastatic Prostate Cancer, Associated Family History Risk

June 18th 2020

The first multidisciplinary, consensus-driven framework for genetic testing in prostate cancer was borne out of the 2019 Philadelphia Prostate Cancer Consensus Conference, leading to the creation of comprehensive guidelines regarding the evaluation, management, and implementation therein.

FDA Approves Pembrolizumab for TMB-High Tumors

June 16th 2020

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.

Dr. Coleman on the Utility of Biomarkers for Precision Medicine in Ovarian Cancer

June 16th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the utility of biomarkers in precision medicine.

Dr. Polsky on the Association Between ctDNA and Survival in Melanoma

June 11th 2020

David Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 11th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 10th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Dr. Lopategui on the Evolution of Targeted Therapies in NSCLC

June 5th 2020

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Analysis Highlights Acquired Resistance Mechanisms in METex14+ NSCLC

June 5th 2020

Mark M. Awad, MD, PhD, discusses the findings from the study, the importance of identifying patients with METex14 mutations, and the importance of understanding acquired resistance in NSCLC.

Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced Cancer

June 5th 2020

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Review Reveals Challenges of NGS Testing in Community Practices, Proactive Measures to Increase Utility

June 3rd 2020

Jennifer Marie Suga, MD, discusses the importance of understanding the current limitations to next-generation sequencing in oncology, the impact of the study findings, and remaining challenges regarding NGS testing in the community setting.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors

June 2nd 2020

The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.

Systematic Review Spotlights Potential Markers for ctDNA Use in CRC

June 2nd 2020

Sander Bach, discusses the rationale for conducting this systematic review in CRC, key inclusion/exclusion criteria, and the potential clinical implications of these findings.

EU Panel Backs Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

June 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non–small cell lung cancer not previously treated with ROS1 inhibitors.